首页> 外文期刊>Acute Medicine & Surgery >Early administration of fibrinogen concentrates improves the short‐term outcomes of severe pelvic fracture patients
【24h】

Early administration of fibrinogen concentrates improves the short‐term outcomes of severe pelvic fracture patients

机译:早期服用浓缩纤维蛋白原可改善重度骨盆骨折患者的近期预后

获取原文
获取外文期刊封面目录资料

摘要

Aim Hemorrhage from pelvic fracture is a major cause of mortality after blunt trauma. Several studies have suggested that early fibrinogen supplementation improves outcomes of traumatic hemorrhage. Thus, we revised our massive transfusion protocol ( MTP ) in April 2013 to include early off‐label administration of fibrinogen concentrate. The objective of this study was to evaluate the impact of the revision on the short‐term outcomes of pelvic fracture patients. Methods This was a single‐center, retrospective, cohort study. A total of 224 consecutive pelvic fracture patients hospitalized in Saitama Medical Center (Saitama, Japan), 115 before the revision (Group E) and 109 after (Group L), were enrolled. Characteristics of the patients were compared between the groups. Impacts of the revision were evaluated by hazard ratios adjusted for characteristics, injury severity, and coagulation status using Cox's multivariate proportional hazard model. The impact was also evaluated by log–rank test and relative risk of 28‐day mortality between the groups. Results The characteristics were equivalent between the groups. The multivariate analysis revealed that the revision of MTP was significantly related to improved survival with an adjusted hazard ratio (95% confidence interval) of 0.45 (0.07–0.97). The log–rank test gave χ~(2)‐test values of 5.2 (P = 0.022) and 6.7 (P = 0.009), and the relative risks were 0.37 (0.15–0.91) and 0.33 (0.13–0.84), in patients with all Injury Severity Scores and Injury Severity Score ≥21, respectively. Conclusion The revision of MTP to include aggressive off‐label treatment with fibrinogen concentrate was related to improved short‐term outcomes of severe pelvic fracture patients. However, due to the limitations of the study, the improvement could not be attributed totally to the revision. Twenty‐eight‐day survival curves of pelvic fracture patients compared between treatment groups. Broken lines represent the curve of Group E (those hospitalized before April 2013) and solid lines represent that of Group L (those hospitalized in April 2013 and later). The curves of patients with all Injury Severity Scores (top) and those of patients with Injury Severity Score ≥21 (bottom) are shown.
机译:目的骨盆骨折引起的出血是钝伤后死亡的主要原因。几项研究表明,早期补充纤维蛋白原可改善创伤性出血的结果。因此,我们在2013年4月修订了我们的大规模输血方案(MTP),以包括早期标签外的纤维蛋白原浓缩物的管理。这项研究的目的是评估修订对骨盆骨折患者短期预后的影响。方法这是一项单中心,回顾性队列研究。在Sa玉医疗中心(日本Sa玉)住院的连续224例骨盆骨折患者入组,翻修前(E组)115例,改组后(L组)109例。比较两组患者的特征。使用Cox的多元比例风险模型,通过针对特性,伤害严重性和凝血状态进行调整的风险比率,评估了修订的影响。还通过对数秩检验和两组之间28天死亡率的相对风险来评估影响。结果各组之间的特征相同。多元分析表明,MTP的修订与生存率显着相关,调整后的危险比(95%置信区间)为0.45(0.07-0.97)。对数秩检验得出χ〜(2)检验值分别为5.2( P = 0.022)和6.7( P = 0.009),相对风险分别为0.37(0.15-0.91)和0.33(0.13) –0.84),所有损伤严重度评分和损伤严重度评分均≥21的患者。结论对MTP的修订包括使用纤维蛋白原浓缩剂进行积极的标签外治疗与重度骨盆骨折患者的近期预后改善有关。但是,由于研究的局限性,改进不能完全归因于修订。比较治疗组之间骨盆骨折患者的28天生存曲线。虚线表示E组(2013年4月之前住院的患者)的曲线,实线表示L组(2013年4月及以后住院的患者)的曲线。显示了所有损伤严重度评分患者的曲线(顶部)和损伤严重度评分≥21的患者的曲线(底部)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号